Twist Biopharma Solutions is committed to collaborating with our partners to develop efficient antibody therapeutics, leveraging our integrated in vitro and in vivo antibody discovery platforms. In this presentation, we showcase the discovery of anti 4-1BB-Nectin-4 bispecific antibodies (bsAbs) using our library of libraries, followed by high-throughput antibody production (HTIgG), surface plasmon resonance (SPR) characterization, and cell-based assays. 4-1BB has gained significant attention as a versatile immunotherapeutic target due to its widespread expression and the ability to activate diverse signaling pathways critical for robust immune responses. Concurrently, Nectin-4 has emerged as an attractive precision medicine target, being notably overexpressed in various solid tumors, including breast, lung, and ovarian cancers. Our top candidates exhibited robust efficacy in signaling assays and immune cell activation assays. These promising results indicate that these candidates merit further exploration in preclinical investigations and potential development as therapeutic antibodies.